Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 15, 2026Endocrine Reviews

Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum

View Full Paper
Ask AI
Bookmark
Share

Authors

KSKonstantinos StefanakisPKP KarakasisDVDimitra Vasdeki

Discussion

Loading...

Member takes

Overview

Review examines the effects of new antidiabetic drugs on cardiovascular, kidney, and metabolic outcomes, suggesting integrated treatment strategies.

Key Points

  • This review aims to explore the role of newer antidiabetic drug classes in managing cardiovascular-kidney-metabolic (CKM) syndrome.
  • Analyzed the impact of SGLT2 inhibitors, GLP-1RAs, and combination therapies on CKM outcomes.
  • Synthesized evidence from pivotal clinical trials related to antidiabetic therapy benefits.
  • Evaluated therapeutic strategies for different stages of CKM syndrome.
  • SGLT2 inhibitors and GLP-1RAs significantly reduce major adverse cardiovascular events and slow CKD progression.
  • Weight-centric incretin therapies are prioritized for obesity and prediabetes management.
  • Layered combination therapy improves cardiovascular and kidney protection in advanced CKM stages.

Cite This Study

Stefanakis et al. (2026) studied this question.

synapsesocial.com/papers/6a57245a88b21df875480ce2https://doi.org/10.1210/endrev/bnag022
View Full Paper
Ask AI
Bookmark
Share